Attentional bias modification is associated with fMRI response toward negative stimuli in individuals with residual depression: a randomized controlled trial

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)

From the Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway (Hilland, Landro, Harmer, Maglanoc, Jonassen); the Division of Psychiatry, Diakonhjemmet Hospital, Oslo, Norway (Hilland, Landro); the Psychopharmacology and Emotional Research Lab, University Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Harmer); the Computational Psychiatry Laboratory, Department of Psychiatry, University of Oxford, Oxford, United Kingdom (Browning); the Oxford Health NHS Trust, Oxford, United Kingdom (Browning); the NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway (Maglanoc); and the Division of Psychiatry, Akerhus University Hospital, Oslo, Norway (Jonassen)